207 related articles for article (PubMed ID: 31120789)
21. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
22. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
23. A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET/CT uptake by primary site-dependent neuroendocrine tumor metastasis.
Kunikowska J; Pawlak D; Kolasa A; Mikołajczak R; Królicki L
Clin Nucl Med; 2014 Oct; 39(10):855-61. PubMed ID: 25072928
[TBL] [Abstract][Full Text] [Related]
24. Somatostatin receptor imaging with [
Zhao L; Pang Y; Wang Y; Chen J; Zhuang Y; Zhang J; Zhao L; Sun L; Wu H; Chen X; Lin Q; Chen H
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1360-1373. PubMed ID: 34665275
[TBL] [Abstract][Full Text] [Related]
25. Head-to-Head Comparison of
Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
[TBL] [Abstract][Full Text] [Related]
26. Parametric Net Influx Rate Images of
Ilan E; Sandström M; Velikyan I; Sundin A; Eriksson B; Lubberink M
J Nucl Med; 2017 May; 58(5):744-749. PubMed ID: 27789716
[No Abstract] [Full Text] [Related]
27. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
28. Outcome prediction of SSTR-RADS-3A and SSTR-RADS-3B lesions in patients with neuroendocrine tumors based on
Gao J; Zhou J; Liu C; Pan Y; Lin X; Zhang Y
J Cancer Res Clin Oncol; 2024 May; 150(5):272. PubMed ID: 38795250
[TBL] [Abstract][Full Text] [Related]
29. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
30. Biodistribution and first clinical results of
Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
[TBL] [Abstract][Full Text] [Related]
31. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
32. The value of Bayesian penalized likelihood reconstruction for improving lesion conspicuity of malignant lung tumors on
Kurita Y; Ichikawa Y; Nakanishi T; Tomita Y; Hasegawa D; Murashima S; Hirano T; Sakuma H
Ann Nucl Med; 2020 Apr; 34(4):272-279. PubMed ID: 32060780
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
34.
Hope TA; Calais J; Zhang L; Dieckmann W; Millo C
J Nucl Med; 2019 Sep; 60(9):1266-1269. PubMed ID: 30850506
[TBL] [Abstract][Full Text] [Related]
35. 68Ga-DOTATATE PET: temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours.
Coura-Filho GB; Hoff AAFO; Duarte PS; Buchpiguel CA; Josefsson A; Hobbs RF; Sgouros G; Sapienza MT
Nucl Med Commun; 2019 Sep; 40(9):920-926. PubMed ID: 31343614
[TBL] [Abstract][Full Text] [Related]
36. Value of the
Fastrez M; Artigas C; Sirtaine N; Wimana Z; Caillet M; Rozenberg S; Flamen P
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():69-74. PubMed ID: 28342392
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at
Ruuska T; Ramírez Escalante Y; Vaittinen S; Gardberg M; Kiviniemi A; Marjamäki P; Kemppainen J; Jyrkkiö S; Minn H
Acta Oncol; 2018 Feb; 57(2):283-289. PubMed ID: 28686510
[TBL] [Abstract][Full Text] [Related]
38. 68Ga-DOTATATE: Significance of Uptake in the Tail of the Pancreas in Patients Without Lesions.
Delbeke D; Newman G; Deppen S; Shah C; Ndolo J; Shi C; Bailey CE; Jessop AC; Sandler MP
Clin Nucl Med; 2019 Nov; 44(11):851-854. PubMed ID: 31524686
[TBL] [Abstract][Full Text] [Related]
39. Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction.
Lasnon C; Salomon T; Desmonts C; Dô P; Oulkhouir Y; Madelaine J; Aide N
Ann Nucl Med; 2017 Feb; 31(2):125-134. PubMed ID: 27812791
[TBL] [Abstract][Full Text] [Related]
40. Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is redifferentiation akin phenomenon a reality in neuroendocrine tumors?
Basu S; Ostwal V
Nucl Med Commun; 2016 Jun; 37(6):669-71. PubMed ID: 27105440
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]